Cellectar Biosciences, Inc.
CLRB · Nasdaq · United States
Share price · CLRB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CLRB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-8.9%
Nothing announced by CLRB that day or the session before.
- 16 Nov 2026-11.4%
Nothing announced by CLRB that day or the session before.
- 4 Nov 2026-6.1%
- 22 Oct 2026-8.6%
Nothing announced by CLRB that day or the session before.
- 14 Oct 2026-15.1%
Nothing announced by CLRB that day or the session before.
- 8 Oct 2026-7.3%
Nothing announced by CLRB that day or the session before.
- 5 Oct 2026-6.2%
Nothing announced by CLRB that day or the session before.
- 25 Sep 2026-13.3%
Nothing announced by CLRB that day or the session before.
- 22 Sep 2026-5.1%
Nothing announced by CLRB that day or the session before.
- 22 Jun 2026-7.9%
Nothing announced by CLRB that day or the session before.
Share of unusual movement by asset
For each asset, the share of CLRB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | phospholipid ether (selective lipid raftRadiopharmaceutical | Multiple MyelomaWaldenstrom's Macroglobulinemia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2032 (1)
January 2032 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $5.4M | $25M | $8.0M-$9.4M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $4.6M | $34M | $6.9M-$6.0M operating cash flow | report ↗ |
| 2026-Q1 | — | $3.0M | $8.3M | $5.7M-$4.8M operating cash flow | report ↗ |
| 2025-Q3 | — | $2.5M | $13M | $4.4M-$4.3M operating cash flow | report ↗ |
| 2025-Q2 | — | $2.4M | $11M | $5.5M-$5.1M operating cash flow | report ↗ |
| 2025-Q1 | — | $3.4M | $14M | $6.6M-$9.4M operating cash flow | report ↗ |
| 2024-Q3 | — | $5.5M | $34M | $15M-$9.2M operating cash flow | report ↗ |
| 2024-Q2 | — | $7.3M | $26M | $0.9M-$14M operating cash flow | report ↗ |
| 2024-Q1 | — | $7.4M | $40M | $22M-$13M operating cash flow | report ↗ |
| 2023-Q3 | — | $7.3M | $19M | $14M-$8.1M operating cash flow | report ↗ |
| 2023-Q2 | — | $6.3M | $5.2M | $8.2M-$7.5M operating cash flow | report ↗ |
| 2023-Q1 | — | $6.7M | $13M | $8.6M-$7.2M operating cash flow | report ↗ |
| 2022-Q3 | — | $5.4M | $18M | $7.8M-$7.0M operating cash flow | report ↗ |
| 2022-Q2 | — | $4.5M | $25M | $7.4M-$5.8M operating cash flow | report ↗ |
| 2022-Q1 | — | $3.9M | $31M | $6.1M-$5.0M operating cash flow | report ↗ |
| 2021-Q3 | — | $3.9M | $40M | $5.8M-$6.4M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $12M | $13M | $5.5M-$23M operating cash flow | report ↗ |
Cellectar Biosciences reported no revenue for the full year 2025, with R&D spend of $11.5M, down 56.0% YoY. Cash and equivalents were $13.2M at year-end, and the company reported a net loss of $21.79M.
The company is on track to submit a Conditional Marketing Authorization application for iopofosine I 131 to the European Medicines Agency in Q3 2026, targeting potential EU commercialization in 2027. It also initiated a Phase 1b dose-finding study of CLR 125 in triple-negative breast cancer, with early data expected by mid-2026, and noted FDA Breakthrough Therapy Designation for iopofosine I 131 in relapsed/refractory Waldenström macroglobulinemia. Management stated cash is expected to fund basic operations into Q3 2026.
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($50K), 1 sale ($732). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-07-08 | Loren Stefan · Consultant | Award / grant (derivative) | 15,000 | — | — | Form 4 |
| 2026-07-08 | Loren Stefan · Consultant | Award / grant (derivative) | 15,000 | — | — | Form 4 |
| 2026-07-07 | NEIS JOHN · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-07-07 | Swirsky Douglas J · director | Award / grant (derivative) | 37,500 | — | — | Form 4 |
| 2026-07-07 | Longcor Jarrod · Chief Operating Officer | Award / grant (derivative) | 118,000 | — | — | Form 4 |
| 2026-07-07 | Gu Andrew · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-07-07 | CARUSO JAMES V · director, President & CEO | Award / grant (derivative) | 250,000 | — | — | Form 4 |
| 2026-07-07 | Chanan-Khan Asher · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 19 reporting institutions held 0.3M shares ($813K, 3.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Bleichroeder LP | 100,000 | $254K |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 81,884 | $208K |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 52,778 | $134K |
| 4 | Riverview Capital Advisers, LLC | 10,384 | $50K |
| 5 | Sequoia Financial Advisors, LLC | 18,850 | $48K |
| 6 | VANGUARD FIDUCIARY TRUST CO | 16,573 | $42K |
| 7 | Warberg Asset Management LLC | 13,900 | $35K |
| 8 | UBS Group AG | 9,647 | $25K |
| 9 | BlackRock, Inc. | 4,745 | $12K |
| 10 | Tower Research Capital LLC (TRC) | 793 | $2K |
| 11 | Vanguard Global Advisers, LLC | 563 | $1K |
| 12 | MORGAN STANLEY | 510 | $1K |
| 13 | TD Waterhouse Canada Inc. | 63 | $154 |
| 14 | SBI Securities Co., Ltd. | 11 | $28 |
| 15 | FMR LLC | 10 | $25 |